Abivax Shares: +9.4% at Opening, Boosted by Acquisition Rumors by Eli Lilly
The French biotechnology company starts the session with a significant increase. The stock is up 9.4%, moving from 100 € the previous day to 109.40 € this morning. This rise occurs in a contrasting stock market environment, with the CAC 40 down by 0.29% at the same time.
Sustained Bullish Momentum
Abivax's performance is in a sustained upward trend. Over the past seven days, the stock has edged up by 1.11%, while over three months, the performance has reached 55.84%. However, the past year remains the most telling indicator, with a gain of 1,450%. Two events explain this acceleration at the beginning of the week: the inclusion of the stock in the Nasdaq Biotechnology Index, effective today, and media reports of a potential acquisition interest from a major American pharmaceutical company. However, volumes remain very limited, with only 0.06% of the capital traded at the opening, indicating an immediate but cautious interest among investors, many of whom are active during the end-of-year holiday season.
Technical Strengths Supporting the Rise
Technically, the stock benefits from a favorable position that explains its ability to advance without immediate exhaustion. Priced at 109.40 €, the share remains well above its fifty-day moving average, set at 93.90 €, reflecting a positive medium-term dynamic. Its positioning well beyond the two-hundred-day moving average (45.73 €) confirms a bullish trend established over several months. The stock is in the upper part of its Bollinger bands, which range between 89.67 € and 117.70 €, signaling a certain intensity of the movement. Its Relative Strength Index, calculated at 45 points, indicates a balanced situation without evident overbuying, offering a theoretical margin for progression. The monthly volatility of 21.15% remains contained, suggesting that the day's progression, although notable, does not occur against a backdrop of extreme turbulence.
Caution Signaled by MACD
The MACD technical signal, however, indicates some caution. The MACD line at 1.11 remains below its signal line positioned at 2.59, creating a bearish configuration that contrasts with the course's progression. This gap may reflect a technical rebound rather than a structural change in trend. The accumulation-distribution index also displays a negative value at -227,901, pointing to an underlying weakness of buying flows despite the visible daily rise. These mixed signals suggest that today's increase responds to news factors rather than a sustainable recovery of buying momentum as measured by momentum indicators.
